Leerink Partners analyst Andrew Berens reiterated an Outperform rating and $334.00 price target on BeOne Medicines (NASDAQ: ONC).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE